Getting Rosalind Franklin’s story right is crucial, because she has become a role model for women going into science https://t.co/wR8fBl5cNJ

Presentation by Dr Stein Steingrimsson suggesting ChatGPT as a co-author, noting that ChatGPT has contributed more than many of his previous co-authors! Unfortunately the journal didn't agree so no co-authorship for ChatGPT. #ISAD2025

Great poster session at ISAD2025!

A huge thank you to all our incredible speakers today –  we can’t wait for what’s to come tomorrow! #ISAD2025 #AffectiveDisorders #DepressionResearch #KingsCollegeLondon #MentalHealthScience #MoodDisorders #ReserchersinAction #ScienceandSnacks

A pre-debate poll showed 64% for the motion. After some persuasive arguments, contested evidence, and a few feisty comments from the audience, the post-debate poll revealed quite a turnaround –  62% against, 30% for, and 8% abstaining! What a way to end the day!

To close the day, we enjoyed the much-anticipated ISAD debate on hyperbolic tapering and its role in discontinuing antidepressants. On the panel arguing for tapering was Prof David Taylor (Maudsley), while against was Assistant Prof Sameer Jauhar (Imperial College London).

Our final keynote of the day came from Professor Ed Bullmore (King’s College London), who explored the complex yet fascinating relationship between inflammation and depression.

Next, we welcomed our second keynote speaker, Professor Mark Frye from the Mayo Clinic, who delivered an engaging talk on the use of stimulants in treating bipolar depression and how they differ from traditional antidepressants and antipsychotics.

We kicked off the afternoon with a dynamic symposium on the personalisation of psychotherapy and pharmacotherapy in depression. Huge thanks to our speakers –  Jaime Delgadillo from King’s, Barney Dunn from Exeter, and Roos van Westrhenen from the Parnassia Psychiatric Institute.

Our first keynote speaker, Professor Kenneth Kaufman (Rutgers Robert Wood Johnson Medical School), then delivered a thought-provoking session on the ethics and current landscape of medical assistance in dying for individuals with mental disorders.

Next up two fantastic talks from Oxford! Mike Browning talked about the pioneering PAX-D study using the Parkinson’s drug pramipexole for treatment-resistant depression, while Philip Cowen gave a fascinating trip down memory lane, revisiting the discovery and evolution of SSRIs

This morning kicked off with inspiring talks showcasing cutting-edge research from here at King’s, including the LQD study comparing lithium vs quetiapine for individuals with treatment-resistant depression.

We’re thrilled to be hosting the 23rd ISAD Meeting here at King’s College London! #ISAD2025 #AffectiveDisorders #DepressionResearch #KingsCollegeLondon #MentalHealthScience #MoodDisorders #ReserchersinAction #ScienceandSnacks

Prof Phil Cowen talking about the history of antidepressants at ISAD2025

Discussing home based neurostimulatory treatments for depression

First Symposium at ISAD2025 is showcasing work going on at The Centre for Affective Disorders @kclcfad at the Institute of Psychiatry, Psychology and Neuroscience

Opening the ISAD2025 London Regional Meeting

Congrats to @MarioJuruena and team here in the Centre for Affective Disorders @kclcfad winning a Team of the Year award from the Royal College of Psychiatrists!

#andthewinneris... Maudsley Advanced Treatment Service (@MaudsleyNHS @KingsIoPPN @MarioJuruena)! The judges were impressed by the way the team involved and engaged key stakeholders, particularly patients and carers, in the work of the Centre, in identifying the research

Short video describing results of the LQD study in treatment resistant depression